Evidence map›Paper›PMID 42345299›Full record

ArticlemAbs2026

Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.

Houcong Jin, Gao Sun, Hongxia Shen, Qian Hao, Lanlan Chen, Chong Che, Xiaoyu Gu, Tong Wang, Nizhi Wang, Fangfang Du and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Houcong JinCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Gao SunCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Hongxia ShenCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Qian HaoCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Lanlan ChenCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Chong CheCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Xiaoyu GuCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Tong WangCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Nizhi WangCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Fangfang DuCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Qingjuan MaCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Peng QiCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Mengyao AnCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Xuemei LiaoCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Xiaozhen WangCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Siqin WangCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Lei JinCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Lishan KangCentral Research Institute, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Weekly formulations of long-acting growth hormone (LAGH) effectively treat growth hormone (GH) deficiency in both children and adults while offering improved convenience compared to daily GH. To further enhance patient convenience and compliance, longer-acting GH preparations have become a key research focus. However, due to the inherent short half-life of protein-based drugs, no ultra-long-acting growth hormone or analog products (with dosing intervals longer than once weekly) are currently available worldwide. In this study, we developed a potentially ultra-long-acting growth hormone receptor (GHR) agonist pH.VHH03 with GH-mimetic activity by engineering hinge region and variable region of a VHH antibody. Through optimization of the hinge region, the

Indexed as

Human Growth HormoneReceptors, SomatotropinAnimalsCell ProliferationHumansHydrogen-Ion ConcentrationInsulin-Like Growth Factor IMaleRatsRats, Sprague-DawleyHuman Growth HormoneInsulin-Like Growth Factor IReceptors, SomatotropinGH mimeticGHR agonistic antibodyhinge regionlong-acting growth hormonepH-dependentVHH antibody

Identifiers

PMID42345299
PMCPMC13313243

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.